Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4^LVFOXP3 in IPEX Syndrome
NCT05241444Phase 1Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD4^LVFOXP3 in immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) (2 cohorts). Primary endpoints: Target cell number for dose manufacturing at Day 0 and Maximum Tolerated Dose. Started Mar 2022; status: active, not recruiting.
02
Drugs
CD4^LVFOXP3
03
Conditions
immune dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)
Beyond the preview
Go deeper on NCT05241444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241444.